{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:34:08Z","timestamp":1779204848940,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Urban Health"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s11524-015-9953-4","type":"journal-article","created":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T15:13:23Z","timestamp":1427987603000},"page":"635-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System"],"prefix":"10.1007","volume":"92","author":[{"given":"John T.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josiah D.","family":"Rich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley W.","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Vohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Spaulding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian T.","family":"Montague","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,1]]},"reference":[{"issue":"8","key":"9953_CR1","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1478-3231.2011.02494.x","volume":"31","author":"E Chak","year":"2011","unstructured":"Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011; 31(8): 1090\u2013101. doi: 10.1111\/j.1478-3231.2011.02494.x .","journal-title":"Liver Int"},{"issue":"5","key":"9953_CR2","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1053\/jhep.2002.36791","volume":"36","author":"W Kim","year":"2002","unstructured":"Kim W. The burden of hepatitis C in the United States. Hepatology. 2002; 36(5): S30\u20134. doi: 10.1053\/jhep.2002.36791 .","journal-title":"Hepatology"},{"issue":"4","key":"9953_CR3","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jhep.2013.11.014","volume":"60","author":"I Ditah","year":"2014","unstructured":"Ditah I, Ditah F, Devaki P, et al. The changing epidemiology of hepatitis C virus infection in the United States: national health and nutrition examination survey 2001 through 2010. J Hepatol. 2014; 60(4): 691\u20138. doi: 10.1016\/j.jhep.2013.11.014 .","journal-title":"J Hepatol"},{"issue":"20","key":"9953_CR4","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMp1302973","volume":"368","author":"SD Holmberg","year":"2013","unstructured":"Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013; 368(20): 1859\u201361. doi: 10.1056\/NEJMp1302973 .","journal-title":"N Engl J Med"},{"key":"9953_CR5","first-page":"1","volume":"61","author":"BD Smith","year":"2012","unstructured":"Smith BD, Morgan RL, Beckett G, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945\u20131965. MMWR Recomm Rep. 2012; 61: 1\u201332.","journal-title":"MMWR Recomm Rep"},{"key":"9953_CR6","unstructured":"Ward JW. The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease. Top Antivir Med. 2013; 21(1): 15\u20139."},{"issue":"3","key":"9953_CR7","first-page":"1","volume":"62","author":"K Bornschlegel","year":"2013","unstructured":"Bornschlegel K, Holtzman D, Klevens M, Ward JW. Evaluation of hepatitis C virus infection testing and reporting\u2014eight U.S. Sites, 2005\u20132011. MMWR. 2013; 62(3): 1\u20135.","journal-title":"MMWR"},{"issue":"Suppl 1","key":"9953_CR8","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/cid\/cis363","volume":"55","author":"BD Smith","year":"2012","unstructured":"Smith BD, Jorgensen C, Zibbell JE, Beckett GA. Centers for disease control and prevention initiatives to prevent hepatitis C virus infection: a selective update. Clin Infect Dis. 2012; 55(Suppl 1): S49\u201353. doi: 10.1093\/cid\/cis363 .","journal-title":"Clin Infect Dis"},{"issue":"8","key":"9953_CR9","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2105\/AJPH.2013.301211","volume":"103","author":"R Mahajan","year":"2013","unstructured":"Mahajan R, Liu SJ, Klevens RM, Holmberg SD. Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004\u20132010. Am J Public Health. 2013; 103(8): 1445\u20139. doi: 10.2105\/AJPH.2013.301211 .","journal-title":"Am J Public Health"},{"issue":"4","key":"9953_CR10","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/ajg.2008.143","volume":"104","author":"DR Hunt","year":"2009","unstructured":"Hunt DR, Saab S. Viral hepatitis in incarcerated adults: a medical and public health concern. Am J Gastroenterol. 2009; 104(4): 1024\u201331. doi: 10.1038\/ajg.2008.143 .","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"9953_CR11","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.2105\/AJPH.2004.056291","volume":"95","author":"G Macalino","year":"2005","unstructured":"Macalino G, Dhawan D, Rich J. A missed opportunity: hepatitis C screening of prisoners. Am J Public Health. 2005; 95(10): 1739\u201340. doi: 10.2105\/AJPH.2004.056291 .","journal-title":"Am J Public Health"},{"issue":"7","key":"9953_CR12","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2105\/AJPH.94.7.1218","volume":"94","author":"GE Macalino","year":"2004","unstructured":"Macalino GE, Vlahov D, Sanford-colby S, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island Prisons. Am J Public Health. 2004; 94(7): 1218\u201323.","journal-title":"Am J Public Health"},{"key":"9953_CR13","author":"B McNamara","year":"2013","unstructured":"McNamara B, Losikoff P, Huguenin L, Macalino GE, Rich JD, Gregory SH. Increasing hepatitis C prevalence and associated risk behaviors among incarcerated young adults. J Urban. 2013. doi: 10.1007\/s11524-013-9807-x .","journal-title":"J Urban"},{"issue":"1","key":"9953_CR14","first-page":"27","volume":"21","author":"A Spaulding","year":"2013","unstructured":"Spaulding A, Kim A, Harzke A, et al. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. Top Antivir Med. 2013; 21(1): 27\u201335. Available at: http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3875217\/ . Accessed March 16, 2014.","journal-title":"Top Antivir Med"},{"key":"9953_CR15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/003335490912400115","volume":"124","author":"J Baillargeon","year":"2009","unstructured":"Baillargeon J, Snyder N, Soloway RD, et al. Hepatocellular carcinoma prevalence and mortality in a male state prison population. Public Health Rep. 2009; 124: 120\u20136.","journal-title":"Public Health Rep"},{"issue":"4","key":"9953_CR16","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/hep.26387","volume":"58","author":"S Larney","year":"2013","unstructured":"Larney S, Kopinski H, Beckwith CG, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013; 58(4): 1215\u201324. doi: 10.1002\/hep.26387 .","journal-title":"Hepatology"},{"issue":"1","key":"9953_CR17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1186\/1471-2458-10-777","volume":"10","author":"E Gough","year":"2010","unstructured":"Gough E, Kempf M, Graham L, et al. HIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis. BMC Public. 2010; 10(1): 777. doi: 10.1186\/1471-2458-10-777 .","journal-title":"BMC Public"},{"issue":"4","key":"9953_CR18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/02791072.2008.10400655","volume":"40","author":"AG Rhodes","year":"2008","unstructured":"Rhodes AG, Taxman FS, Friedmann PD, Cropsey KL. HCV in incarcerated populations: an analysis of gender and criminality on risk. J Psychoactive Drugs. 2008; 40(4): 493\u2013501. doi: 10.1080\/02791072.2008.10400655 .","journal-title":"J Psychoactive Drugs"},{"issue":"1","key":"9953_CR19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2105\/AJPH.2008.147629","volume":"100","author":"CK Martin","year":"2010","unstructured":"Martin CK, Hostetter JE, Hagan JJ. New opportunities for the management and therapy of hepatitis C in correctional settings. Am J Public Health. 2010; 100(1): 13\u20137. doi: 10.2105\/AJPH.2008.147629 .","journal-title":"Am J Public Health"},{"issue":"1","key":"9953_CR20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1006\/pmed.1998.0418","volume":"28","author":"A Spaulding","year":"1999","unstructured":"Spaulding A, Greene C, Davidson K, Schneidermann M, Rich J. Hepatitis C in state correctional facilities. Prev Med (Baltim). 1999; 28(1): 92\u2013100. doi: 10.1006\/pmed.1998.0418 .","journal-title":"Prev Med (Baltim)"},{"key":"9953_CR21","unstructured":"Estelle v. Gamble, 429 US Supreme Court\u00a097 (1976).\u00a0Accessed July 15, 2014."},{"issue":"20","key":"9953_CR22","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1056\/NEJMp1311941","volume":"370","author":"JD Rich","year":"2014","unstructured":"Rich JD, Allen SA, Williams BA. Responding to hepatitis C through the criminal justice system. N Engl J Med. 2014; 370(20): 1871\u20134. doi: 10.1056\/NEJMp1311941 .","journal-title":"N Engl J Med"},{"issue":"4","key":"9953_CR23","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"M Ghany","year":"2009","unstructured":"Ghany M, Strader D, Thomas D, Seeff L. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4): 1335\u201374. doi: 10.1002\/hep.22759 .","journal-title":"Hepatology"},{"issue":"7","key":"9953_CR24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/MCG.0b013e31818dd94c","volume":"43","author":"KW Chew","year":"2009","unstructured":"Chew KW, Allen SA, Taylor LE, Rich JD, Feller E. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. J Clin Gastroenterol. 2009; 43(7): 686\u201391.","journal-title":"J Clin Gastroenterol"},{"key":"9953_CR25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.7326\/0003-4819-138-3-200302040-00010","volume":"138","author":"SA Allen","year":"2003","unstructured":"Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003; 138: 187\u201391.","journal-title":"Ann Intern Med"},{"issue":"7","key":"9953_CR26","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1086\/591707","volume":"47","author":"DS-R Maru","year":"2008","unstructured":"Maru DS-R, Bruce RD, Basu S, Altice FL. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis. 2008; 47(7): 952\u201361. doi: 10.1086\/591707 .","journal-title":"Clin Infect Dis"},{"issue":"5","key":"9953_CR27","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1572-0241.2004.30310.x","volume":"99","author":"RK Sterling","year":"2004","unstructured":"Sterling RK, Hofmann CM, Luketic VA. Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response? Am J Gastroenterol. 2004; 99(5): 866\u201372. doi: 10.1111\/j.1572-0241.2004.30310.x .","journal-title":"Am J Gastroenterol"},{"issue":"20","key":"9953_CR28","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368(20): 1878\u201387. doi: 10.1056\/NEJMoa1214853 .","journal-title":"N Engl J Med"},{"issue":"20","key":"9953_CR29","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","volume":"368","author":"I Jacobson","year":"2013","unstructured":"Jacobson I, Gordon S, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368(20): 1867\u201377. doi: 10.1056\/NEJMoa1214854 .","journal-title":"N Engl J Med"},{"key":"9953_CR30","unstructured":"US Department of Health and Human Services.\u00a0FDA approves Viekira Pak to treat hepatitis C. US Food and Drug Administration. 2014. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm427530.htm . Published December 19, 2014. Accessed February 1, 2015."},{"key":"9953_CR31","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","volume":"370","author":"JJ Feld","year":"2014","unstructured":"Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370: 1594\u2013603. doi: 10.1056\/NEJMoa1315722 .","journal-title":"N Engl J Med"},{"key":"9953_CR32","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","volume":"370","author":"P Ferenci","year":"2014","unstructured":"Ferenci P, Bernstein D, Lalezari J, et al. ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370: 1983\u201392. doi: 10.1056\/NEJMoa1402338 .","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"9953_CR33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/liv.12405","volume":"34","author":"S Pol","year":"2014","unstructured":"Pol S, Vallet-Pichard A, Corouge M. Treatment of hepatitis C virus genotype 3-infection. Liver Int. 2014; 34(Suppl 1): 18\u201323. doi: 10.1111\/liv.12405 .","journal-title":"Liver Int"},{"issue":"3","key":"9953_CR34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370(3): 211\u201321. doi: 10.1056\/NEJMoa1306218 .","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"9953_CR35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/liv.12408","volume":"34","author":"ML Shiffman","year":"2014","unstructured":"Shiffman ML, Benhamou Y. HCV F1\/F2 patients: treat now or continue to wait. Liver Int. 2014; 34(Suppl 1): 79\u201384. doi: 10.1111\/liv.12408 .","journal-title":"Liver Int"},{"key":"9953_CR36","doi-asserted-by":"crossref","unstructured":"Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: Is it worth it? Hepatology. 2014;59(4):1246\u20139. doi: 10.1002\/hep.27039 .","DOI":"10.1002\/hep.27039"},{"key":"9953_CR37","unstructured":"Japsen B. As Pricey Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles. Forbes. 2014. http:\/\/www.forbes.com\/sites\/brucejapsen\/2014\/10\/10\/as-hepatitis-pill-harvoni-joins-sovaldi-states-erect-medicaid-hurdles\/ .\u00a0Published October 10 2014. Accessed Novemer 23, 2014."},{"key":"9953_CR38","unstructured":"Associated Press. Oregon Medicaid targets expensive hepatitis drug. The Washington Post. 2014. http:\/\/www.washingtonpost.com\/national\/health-science\/oregon-medicaid-targets-expensive-hepatitis-drug\/2014\/07\/31\/4af1855a-1912-11e4-88f7-96ed767bb747_story.html . Published July 31, 2014. Accessed November 23, 2014."},{"issue":"8","key":"9953_CR39","doi-asserted-by":"crossref","first-page":"546","DOI":"10.7326\/M14-0602","volume":"161","author":"S Liu","year":"2014","unstructured":"Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in u.s. Incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014; 161(8): 546\u201353. doi: 10.7326\/M14-0602 .","journal-title":"Ann Intern Med"},{"issue":"3","key":"9953_CR40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.7326\/0003-4819-138-3-200302040-00021","volume":"138","author":"T Hammett","year":"2003","unstructured":"Hammett T. Adopting more systematic approaches to hepatitis C treatment in correctional facilities. Ann Intern Med. 2003; 138(3): 235\u20136. Available at: http:\/\/annals.org\/article.aspx?articleid=716017 . Accessed March 15, 2014.","journal-title":"Ann Intern Med"},{"issue":"7","key":"9953_CR41","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/MCG.0b013e31818dd94c","volume":"43","author":"K Chew","year":"2009","unstructured":"Chew K, Allen SA, Taylor LE, Rich JD, Feller E. Treatment outcomes with pegylated interferon and ribavriin for male prisoners with chronic hepatitis C. J Clin Gastroenterol. 2009; 43(7): 686\u201391. doi: 10.1097\/MCG.0b013e31818dd94c .","journal-title":"J Clin Gastroenterol"},{"issue":"7","key":"9953_CR42","first-page":"A3","volume":"15","author":"B Gregory","year":"2008","unstructured":"Gregory B, Van Horn C, Kaprielian VS. 8 steps to a chart audit for quality. Fam Pract Manag. 2008; 15(7): A3\u20138. Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18763679 . Accessed December 11, 2014.","journal-title":"Fam Pract Manag"},{"key":"9953_CR43","unstructured":"State of Rhode Island and Providence Plantations. Budget Fiscal Year 2014 Volume IV - Public Safety, Natural Resources, and Transportation. http:\/\/www.budget.ri.gov\/Documents\/PriorYearBudgets\/OperatingBudget2014\/BudgetVolumeIV\/2_DepartmentOfCorrections.pdf .\u00a0Accessed April 15, 2014."},{"issue":"9956","key":"9953_CR44","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2015","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2015; 384(9956): 1756\u201365. doi: 10.1016\/S0140-6736(14)61036-9 .","journal-title":"Lancet"},{"key":"9953_CR45","doi-asserted-by":"crossref","unstructured":"Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. N Engl J Med. 2014:1889\u20131898. doi: 10.1056\/NEJMoa1402454 .","DOI":"10.1056\/NEJMoa1402454"},{"key":"9953_CR46","unstructured":"Federal Bureau of Prisons.\u00a0Interim Guidance for the Management of Chronic Hepatitis C Infection.\u00a0 http:\/\/www.bop.gov\/resources\/pdfs\/hepatitis_c_current.pdf . Accessed July 15, 2014."},{"issue":"11","key":"9953_CR47","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2893.2008.01008.x","volume":"15","author":"AJ Sutton","year":"2008","unstructured":"Sutton AJ, Edmunds WJ, Sweeting MJ, Gill ON. The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis. J Viral Hepat. 2008; 15(11): 797\u2013808. doi: 10.1111\/j.1365-2893.2008.01008.x .","journal-title":"J Viral Hepat"},{"issue":"10","key":"9953_CR48","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/cid\/cit069","volume":"56","author":"MH Eckman","year":"2013","unstructured":"Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE. Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis. 2013; 56(10): 1382\u201393. doi: 10.1093\/cid\/cit069 .","journal-title":"Clin Infect Dis"},{"key":"9953_CR49","first-page":"1","volume":"2015","author":"ZM Younossi","year":"2014","unstructured":"Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir\/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2014; 2015: 1\u201320. doi: 10.1111\/apt.13081 .","journal-title":"Aliment Pharmacol Ther"},{"key":"9953_CR50","unstructured":"Sanger-Katz M. Why the Hepatitis Cure Sovaldi is a Budgetary Disaster for Prisons. New York Times. http:\/\/www.nytimes.com\/2014\/08\/07\/upshot\/why-the-hepatitis-cure-sovaldi-is-a-budgetary-disaster-for-prisons.html?_r=0&abt=0002&abg=1 . Published August 7 2014.\u00a0Accessed November 23, 2014."},{"issue":"2","key":"9953_CR51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/00333549071220S216","volume":"122","author":"S Klein","year":"2007","unstructured":"Klein S, Wright L, Birkhead G, et al. Promoting HCV treatment completion for prison inmates: New York State\u2019s hepatitis C continuity program. Public Health Rep. 2007; 122(2): 83\u20138.","journal-title":"Public Health Rep"},{"issue":"9055","key":"9953_CR52","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","volume":"349","author":"T Poynard","year":"1997","unstructured":"Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997; 349(9055): 825\u201332. doi: 10.1016\/S0140-6736(96)07642-8 .","journal-title":"Lancet"},{"issue":"5","key":"9953_CR53","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","volume":"10","author":"JA Mauskopf","year":"2007","unstructured":"Mauskopf JA, Sullivan SD, Annemans L. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices\u2014budget impact analysis. Value Health. 2007; 10(5): 336\u201347. doi: 10.1111\/j.1524-4733.2007.00187.x .","journal-title":"Value Health"}],"container-title":["Journal of Urban Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11524-015-9953-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11524-015-9953-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11524-015-9953-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T04:25:54Z","timestamp":1717820754000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11524-015-9953-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,1]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["9953"],"URL":"https:\/\/doi.org\/10.1007\/s11524-015-9953-4","relation":{},"ISSN":["1099-3460","1468-2869"],"issn-type":[{"value":"1099-3460","type":"print"},{"value":"1468-2869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,1]]}}}